SARS-CoV-2 evolution has undergone several mutations since its initial emergence in late 2019. Successive mutations are a com- mon characteristic of RNA viruses like coronavirus. The emergence of new variants is a result of mutations that differ in their characteristics such as their infectiousness and mortality. Several variants of concern have been identified since the start of the pandemic, including Alpha, Beta, Gamma, Delta, and Omicron. Each of these variants showed unique mutations that raised con- cerns about their transmission rate, disease severity, and vaccine efficacy. The omicron variant (XBB 1.6), also known as B.1.1.529, attracted significant attention due to its high number of mutations, particularly in the spike protein. These mutations have raised concerns about potential impacts on vaccine efficacy and their ability to evade immunity. The effectiveness of exist- ing vaccines against omicron and other variants may vary. Public health authorities and researchers worldwide are working to adapt strategies and develop new tools to combat the pandemic effectively. Booster doses have been recommended to enhance immunity, especially in the face of emerging variants. Rapid genome sequencing and analysis of the new variants are essential for monitoring their spread and understanding their characteristics. This helps in adapting public health measures and vaccine strategies accordingly. Developing a multivalent vaccine that can generate a broad immune response, capable of addressing multi- ple variants, is an important consideration in vaccine research and development.